Page 2 - சத்தீஷ் சந்திரன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Potential effectiveness against multiple variants reduces the possibility of mutant virus escape According to World Health Organization, the double mutant variant of SARS-CoV-2 has spread to at least 17 countries MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that in a new study, scientists at Indian Council of Medical Research (ICMR)-National Institute of Virology have found that COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2. As previously disclosed, a study conducted by ICMR also suggested that COVAXIN was effective against the UK variant, B.1.1.7, as well as the Indian double mutant variant, B.1.617. It is notable that the Brazilian variant, B1.128.2, contains the E484K mutation that was found in New York.

New yorkUnited statesAndhra pradeshUnited kingdomSatish chandranSanjay subramanianShankar musunuriChiron behringNational institute of virologyWorld health organizationHead of corpDrug administrationIndian council of medical researchOcugen incExchange commissionIndian council